# A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.

> **NCT02225652** · PHASE2 · COMPLETED · sponsor: **Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS** · enrollment: 11 (actual)

## Conditions studied

- Women With Primary Breast Cancer

## Interventions

- **DRUG:** FEC (Fluorouracil, Epirubicin, Cyclophosphamide) + filgrastim + paclitaxel

## Key facts

- **NCT ID:** NCT02225652
- **Lead sponsor:** Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2013-09
- **Final completion:** 2014-07
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2014-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02225652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02225652, "A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02225652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*